Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, et al.
Japanese Journal of Clinical Oncology|May 16, 2019
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancerHiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2024
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancerAkihiro Tamiya, Mitsuo Osuga, Daijiro Harada, et al.
BMC Pulmonary Medicine|August 24, 2024
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance statusYoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, et al.
Cancer Medicine|April 5, 2025
Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational StudyAkihiro Tamiya, Yasuyuki Mizumori, Mitsuo Osuga, et al.
International Journal of Clinical Oncology|May 9, 2022
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, et al.
Asia-Pacific Journal of Clinical Oncology|April 3, 2019
A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangementDaijiro Harada, Toshiyuki Kozuki, Naoyuki Nogami, et al.
Cancer Science|July 28, 2015
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma modelDaisuke Minami, Nagio Takigawa, Yuka Kato, et al.
Cureus|July 24, 2025
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 StudySho Saeki, Katsuyuki Hotta, Shinya Sakata, et al.
Japanese Journal of Clinical Oncology|September 2, 2020
Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patientsToshio Kubo, Hiromi Watanabe, Kiichiro Ninomiya, et al.
Pageof 7